Drug Guidance for Subsidy 01/07/2022 Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg... See all × 01/07/2022 Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for adults to: treat deep vein thrombosis (DVT) and pulmonary embolism (PE); and prevent recurrent DVT and PE. Subsidy status RRivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. NRMAF assistance do not apply to the following: the use of rivaroxaban for isolated distal DVT; or rivaroxaban 2.5 mg and 10 mg tablets. RApixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL). NRSDL subsidy or MAF assistance do not apply to any strengths of dabigatran. 01/07/2022 Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg... See all × 01/07/2022 Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with NVAF and: CHA2DS2-VASc score of 1 or more for men; and CHA2DS2-VASc score of 2 or more for women. Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral stenosis), or patients with prosthetic heart valves. Subsidy status RRivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. RApixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL). NRSDL subsidy or MAF assistance do not apply to any strengths of dabigatran.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 2.5 mg Alexandra Hospital Changi General Hospital Institute of Mental Health Khoo Teck Puat Hospital National Cancer Centre National Heart Centre National Healthcare Group Polyclinics Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital SingHealth Polyclinics Tan Tock Seng Hospital Woodlands Health Campus Tablet 5 mg Alexandra Hospital Changi General Hospital Institute of Mental Health KK Women's and Children's Hospital Khoo Teck Puat Hospital National Cancer Centre National Heart Centre National Healthcare Group Polyclinics Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital SingHealth Polyclinics Tan Tock Seng Hospital Woodlands Health Campus
ORAL Select a brand starting with the letter: E ELIQUIS TABLET 2.5MG [SIN14279P] ELIQUIS TABLET 5MG [SIN14407P]